Biosimilar Cyltezo® shows similar clinical outcomes to Humira® in treatment of moderate-to-severe chronic plaque psoriaris

Published date27 April 2021
Subject MatterClinical Trials,Prescription Drugs,Biosimilars,Pharmaceutical Industry
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT